NIH-funded study finds semaglutide may slow aging in healthy mice beyond calorie restriction effects

A National Institutes of Health-funded study tested semaglutide, the active ingredient in Ozempic and Wegovy, in older healthy mice. The drug extended median lifespan by nearly 100 days and improved memory, muscle function, and metabolic health. These effects were observed in mice already showing signs of aging, suggesting potential for intervention even after aging has progressed. The study also noted reductions in inflammation and tissue decline, key markers of biological aging.

The research directly compared semaglutide with calorie restriction, a well-established method for extending lifespan in animals. While both approaches produced similar benefits, semaglutide outperformed calorie restriction in areas like cognitive function, blood sugar maintenance, and metabolic rate. This divergence implies that GLP-1 drugs may engage a separate biological pathway, one that could offer additional anti-aging effects beyond those achieved by dietary changes alone.

The findings raise questions about whether GLP-1 drugs could influence human aging. While the results in mice are promising, they do not guarantee similar outcomes in people. Human trials will be necessary to determine if semaglutide or other GLP-1 agonists can slow aging or extend lifespan in healthy older adults. The study’s authors suggest future research should explore these drugs in populations without obesity or diabetes to isolate potential longevity benefits.

For engineers and researchers in biotechnology or pharmaceuticals, this study highlights a potential new avenue for drug development. If GLP-1 drugs do target aging mechanisms, they could become a tool for addressing multiple age-related diseases simultaneously. However, the path from preclinical findings to clinical applications is long, and the costs of developing and validating such treatments would be substantial. The study also underscores the need for robust biomarkers to measure aging in humans, which remains a challenge in longevity research.